Canntab Therapeutics Limited (TBF1.F)
| Previous Close | 0.4540 |
| Open | 0.4720 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.4720 - 0.4720 |
| 52 Week Range | 0.3780 - 0.7250 |
| Volume | 2,500 |
| Avg. Volume | 822 |
| Market Cap | 16.791M |
| Beta (5Y Monthly) | 1.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0600 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- CNW Group
Canntab Announces the Early Exercise of $1,259,250 Warrants
Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the receipt of C$1,259,250 in gross proceeds from the early exercise of 1,679,000 warrants into common shares (the "Warrants"). The Warrants were issued in the final week of May and each Warrant was exercised into 1 common share in the capital of the Company at $0.75. T
- CNW Group
Canntab Mourns the Loss of Co-Founder
Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, announces, with very heavy hearts, the passing of Jeffrey Ward Renwick, the Company's Co-Founder, Director and President. After a long and difficult 15 month battle, Jeff succumbed to his lung cancer at the young age of 54 years.
- CNW Group
Canntab Receives Export License Approval from Health Canada
Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that Health Canada has granted the company an Export License.
